Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Questions?

REQUEST A MEDICAL SCIENCE LIAISON (MSL)

Treatment Recommendations

Add UPTRAVI® Earlier as Part of Comprehensive Treatment for FC II and FC III PAH1,2

#1 most-prescribed oral prostacyclin pathway therapy in PAH image

TREATMENT Recommendations

lung icon

2022 ESC/ERS GUIDELINES: UPTRAVI® is the only prostacyclin pathway therapy to receive the highest class recommendation (Class I, Level B) for sequential triple- and dual-combination therapy2

2022 ESC/ERS Guidelines recommendations image
  • Class I recommendation definition: evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective
  • Level B evidence definition: data derived from a single randomized clinical trial or large nonrandomized studies

THE 6TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION: Escalation to triple-combination therapy is recommended when the initial treatment approach with double-combination therapy results in an intermediate risk status5


In appropriate patients with PAH, guidelines and evidence support earlier escalation to triple-combination therapy2,5*